| Name | XL413 hydrochloride |
| Description | XL413 hydrochloride (BMS-863233 Hydrochloride) is a potent, selective and ATP competitive inhibitor of Cdc7, with an IC 50 of 3.4 nM. XL413 hydrochloride also exhibits potent effect with IC 50 s of 215, 42 nM on CK2, PIM1, respectively, and an EC 50 of 118 nM on pMCM. |
| In vitro | XL413 (BMS-863233) hydrochloride effectively inhibits cell proliferation (IC 50 = 2685 nM), reduces cell viability (IC 50 = 2142 nM), and increases caspase 3/7 activity (EC 50 = 2288 nM) in Colo-205 cells. Additionally, it significantly suppresses the anchorage-independent growth of Colo-205 cells in soft agar (IC 50 = 715 nM) [1]. Demonstrating cytotoxic effects, XL413 hydrochloride has IC 50 values of 22.9 μM in HCC1954 cells and 1.1 μM in Colo-205 cells. It triggers apoptosis in Colo-205 cells without affecting HCC1954 cells. As a DDK inhibitor, XL413 shows potent activity in vitro (IC 50 = 22.7 nM), yet fails to inhibit DDK-dependent Mcm2 phosphorylation in HCC1954 cells, while remaining effective in Colo-205 cells [2]. |
| In vivo | XL413 (BMS-863233; 100 mg/kg, p.o.) hydrochloride shows excellent plasma exposure and favorable pharmacokinetic properties in mice. Additionally, XL413 hydrochloride (10, 30, or 100 mg/kg, p.o.) is well tolerated at all tested doses without significant body weight loss [1]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 2.5 mg/mL (7.66 mM), Sonication is recommended.
H2O : 4.76 mg/mL (14.59 mM), Sonication is recommended.
|
| Keywords | XL-413 | XL 413 Hydrochloride | XL 413 | Pim1 | CK2 | Cdc7 | CaseinKinase | Casein Kinase | BMS863233 Hydrochloride | BMS863233 | BMS 863233 Hydrochloride | BMS 863233 |
| Inhibitors Related | Ribociclib | Amantadine | 2-Chloropyrazine | Kojic acid | Casein | Abemaciclib | 2,4,6-Trihydroxybenzoic acid | N-Cbz-DL-tryptophan | Palbociclib | Abemaciclib methanesulfonate | Sodium Oxamate | Dinaciclib |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
United States
